Psmc2-KO Mouse
一般名
Psmc2-KO
製品ID
S-KO-18253
背景情報
C57BL/6JCya
系統ID
KOCMP-19181-Psmc2-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Psmc2-KO Mouse(カタログ番号S-KO-18253)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Psmc2-KO
系統ID
KOCMP-19181-Psmc2-B6J-VB
遺伝子名
製品ID
S-KO-18253
遺伝子別名
--
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 5
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000030769
NCBIトランスクリプトID
NM_011188
ターゲット領域
Exon 4
有効領域の大きさ
~0.1 kb
遺伝子研究の概要
Psmc2, Proteasome 26S subunit, ATPase 2, is an essential part of the 19S regulatory complex of the 26S proteasome. It catalyzes the unfolding and transport of substrates into the 20S proteasome, playing a crucial role in proteasome-mediated protein degradation, which is involved in multiple cellular processes such as cell cycle regulation, apoptosis, and DNA damage repair [6]. Gene knockout or knockdown models are valuable for studying its functions.
Knockdown of Psmc2 has been shown to have significant impacts in various cancers. In oral squamous cell carcinoma (OSCC), Psmc2 knockdown inhibited cell proliferation, migration, and promoted apoptosis via the PI3K/Akt pathway, suppressing tumor growth [1]. In glioma, it inhibited cell proliferation and promoted apoptosis, and in skin cutaneous melanoma, it suppressed tumor progression by inhibiting cell proliferation, migration, DNA damage, and inducing apoptosis and cell cycle arrest [2,3]. Similar anti-tumor effects were observed in gastric cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, ovarian cancer, and pancreatic cancer, with Psmc2 knockdown affecting cell growth, apoptosis, and migration through various pathways like RPS15A/mTOR, AKT, and by regulating related proteins [4,5,7,8,9].
In conclusion, Psmc2 plays a critical role in promoting the progression of multiple cancers by regulating cell growth, apoptosis, and migration. Studies using Psmc2 knockdown models have revealed its oncogenic functions in various disease areas, suggesting that targeting Psmc2 could be a potential therapeutic strategy for these cancers.
References:
1. Wang, Zijia, Xiong, Haofeng, Zuo, Yijie, Zhu, Chao, Min, Anjie. 2022. PSMC2 knockdown inhibits the progression of oral squamous cell carcinoma by promoting apoptosis via PI3K/Akt pathway. In Cell cycle (Georgetown, Tex.), 21, 477-488. doi:10.1080/15384101.2021.2021722. https://pubmed.ncbi.nlm.nih.gov/34979867/
2. Zheng, Xiaoyang, Wang, Yuguang, Wang, Dongxu, Mu, Zhuang, Hu, Nan. 2022. PSMC2 is overexpressed in glioma and promotes proliferation and anti-apoptosis of glioma cells. In World journal of surgical oncology, 20, 84. doi:10.1186/s12957-022-02533-1. https://pubmed.ncbi.nlm.nih.gov/35287689/
3. Yang, Yanwen, Qi, Fazhi, Wei, Chuanyuan, Luan, Wenjie, Gu, Jianying. 2021. PSMC2 knockdown suppressed tumor progression of skin cutaneous melanoma. In Cell death discovery, 7, 323. doi:10.1038/s41420-021-00727-2. https://pubmed.ncbi.nlm.nih.gov/34716318/
4. Liu, Tao, Zhang, Junling, Chen, Hu, Jiang, Yong, Yang, Zhen. 2022. PSMC2 promotes the progression of gastric cancer via induction of RPS15A/mTOR pathway. In Oncogenesis, 11, 12. doi:10.1038/s41389-022-00386-7. https://pubmed.ncbi.nlm.nih.gov/35256584/
5. Su, Jin, Hu, Shousen, Ding, Shiping, Feng, Kun. 2024. PSMC2 knockdown exerts an anti-tumor role in nasopharyngeal carcinoma through regulating AKT signaling pathway. In Cell cycle (Georgetown, Tex.), 22, 2381-2391. doi:10.1080/15384101.2023.2293590. https://pubmed.ncbi.nlm.nih.gov/38123344/
6. Huang, Wei, Qian, Zhengtao, Shi, Yuxin, Xu, Junying, Ding, Junli. 2023. PSMC2 is a Novel Prognostic Biomarker and Predicts Immunotherapeutic Responses: From Pancreatic Cancer to Pan-Cancer. In Pharmacogenomics and personalized medicine, 16, 747-758. doi:10.2147/PGPM.S418533. https://pubmed.ncbi.nlm.nih.gov/37581119/
7. Duan, Xuhua, Li, Hao, Wang, Manzhou, Han, Xinwei, Ren, Jianzhuang. 2021. PSMC2/ITGA6 axis plays critical role in the development and progression of hepatocellular carcinoma. In Cell death discovery, 7, 217. doi:10.1038/s41420-021-00585-y. https://pubmed.ncbi.nlm.nih.gov/34413286/
8. Zhu, Dawei, Huang, Jie, Liu, Ning, Li, Wei, Yan, Limei. 2021. PSMC2/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration. In Cell death & disease, 12, 730. doi:10.1038/s41419-021-03981-5. https://pubmed.ncbi.nlm.nih.gov/34294689/
9. Qin, Jing, Wang, Wangsheng, An, Fangmei, Huang, Wei, Ding, Junli. 2019. PSMC2 is Up-regulated in Pancreatic Cancer and Promotes Cancer Cell Proliferation and Inhibits Apoptosis. In Journal of Cancer, 10, 4939-4946. doi:10.7150/jca.27616. https://pubmed.ncbi.nlm.nih.gov/31598166/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
